Patents Examined by Kelaginamane Hiriyanna
-
Patent number: 10034900Abstract: An object of the present invention is to provide a method of producing a myeloid blood cell possessing a proliferative capability. According to the present invention, provided is a method of producing a myeloid blood cell possessing a proliferative capability, including forcedly expressing (A) a cMYC gene, and (B) at least one gene selected from the group consisting of a BMI1 gene, an EZH2 gene, an MDM2 gene, an MDM4 gene, and an HIF1A gene in a myeloid blood cell.Type: GrantFiled: September 28, 2011Date of Patent: July 31, 2018Assignee: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITYInventor: Satoru Senju
-
Patent number: 10022403Abstract: The present disclosure provides novel methods for increasing ?-cell viability in islets by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to the islets. The disclosure also provides novel methods for treating a disease or condition in a subject, such as type 1 diabetes mellitus, by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to islets and transplanting the islets into the subject to treat the disease or condition. Kits and compositions including RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, are also provided to increase ?-cell viability.Type: GrantFiled: March 16, 2015Date of Patent: July 17, 2018Assignee: CITY OF HOPEInventors: Sanjay Awasthi, Sushma Yadav, Ismail Al Abdullah, Fouad Kandeel, Brian McFadden, Indu Nair, Sharad S. Singhal
-
Patent number: 10016458Abstract: The invention provides, inter alia, methods for treating vascular deficiencies, including those in diabetic subjects, by transplanting endothelial progenitor cells with transiently reduced p53 expression.Type: GrantFiled: March 11, 2013Date of Patent: July 10, 2018Assignee: Baystate Health, Inc.Inventor: Sabyasachi Sen
-
Patent number: 9986721Abstract: The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted H2 class I gene, a disrupted H2 class II gene, a functional HLA class I transgene, and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both H2 class I and class II molecules, wherein the transgenic mouse comprises a functional HLA class I transgene and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cell has the genotype HLA-A2+HLA-DR1+?2m°IA?°. The invention also relates to methods of using a transgenic mouse of the invention.Type: GrantFiled: July 17, 2012Date of Patent: June 5, 2018Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Claude Auriault, Véronique Pancre, Yu-Chun Lone, Anthony Pajot, François Lemonnier
-
Patent number: 9950016Abstract: The present invention relates to the use of secreted proteins from mesenchymal stem cells and other cells for the treatment of myocardial infarction. In particular, the invention provides compositions and methods based on secreted proteins from mesenchymal stem cells and the genes encoding them.Type: GrantFiled: June 25, 2012Date of Patent: April 24, 2018Assignee: NATIONAL UNIVERSITY OF IRELAND, GALWAYInventors: Timothy O'Brien, Frank Barry, Claire Kavanagh
-
Patent number: 9228007Abstract: Disclosed herein are recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells. The recombinant human progenitor cells are made by transducing a human hematopoietic stem cell with a vector having a nucleic acid molecule which encodes a human T cell receptor specific to a virus, such as Human Immunodeficiency Virus, or an epitope thereof. The recombinant human progenitor cells differentiate and mature into the engineered human thymocytes and the engineered human T cells. Also disclosed herein are methods of inhibiting, reducing or treating a viral infection in a subject, such as a human subject, which comprises administering recombinant human progenitor cells, engineered human thymocytes, and/or engineered human T cells to the subject.Type: GrantFiled: March 10, 2011Date of Patent: January 5, 2016Assignee: The Regents of the University of CaliforniaInventors: Scott G. Kitchen, Jerome A. Zack, Otto O. Yang, Michael S. Bennett, Balamurugan Arumugam
-
Patent number: 8173613Abstract: The present invention relates to compositions and methods for the modulation of metastatic and mesenchymal cell growth and mobility via the regulation of the formation of Twist/Twist homodimers and Twist/E heterodimers. The present invention also relates to methods for screening agents and compound libraries for molecules that function to modulate the formation of Twist/Twist homodimers, Twist/E protein heterodimers or their upstream or downstream effector molecules.Type: GrantFiled: September 22, 2006Date of Patent: May 8, 2012Assignee: Maine Medical CenterInventor: Douglas B. Spicer
-
Patent number: 7998704Abstract: In certain aspects the present invention provides methods and compositions related to contrast agents for magnetic resonance imaging. In certain variations, contrast agents provided herein are generated in situ via genetic instructions and become potent upon sequestering available metal atoms. Exemplary contrast agents include metal-binding proteins.Type: GrantFiled: March 14, 2005Date of Patent: August 16, 2011Assignee: Carnegie Mellon UniversityInventors: Eric T. Ahrens, Clinton S. Robison
-
Patent number: 7906308Abstract: In certain aspects, the invention relates to methods for identifying compounds which modulate Akt activity mediated by the rictor-mTOR complex and methods for treating or preventing a disorder that is associated with aberrant Akt activity.Type: GrantFiled: January 27, 2006Date of Patent: March 15, 2011Assignee: Whitehead Institute for Biomedical ResearchInventors: David M. Sabatini, Dos D. Sarbassov
-
Patent number: 7892834Abstract: A gene complex-forming material which comprises a water-soluble polymer having a peptide containing an amino acid sequence serving as the substrate of an intracellular signal-responsive enzyme and basic amino acids imparting cationic nature; a gene complex composed of this gene complex-forming material with a gene; and a gene transfer method and a gene transfer agent with the use of the same. Namely, a novel material and a method wherein the cationic moiety of the peptide and the gene form a rigid ion complex to give a stable gene complex, and, upon a cellular signal response, the positive charge of the cationic moiety of the peptide is neutralized or disappears and the gene complex is broken in the cell to thereby release the gene, thus activating the gene transferred into specific cells. The neutralization or disappearance of the positive charge can be achieved by, for example, phosphorylation with protein kinase A or cleavage by caspase.Type: GrantFiled: October 16, 2001Date of Patent: February 22, 2011Assignee: Japan Science and Technology AgencyInventor: Yoshiki Katayama
-
Patent number: 7799565Abstract: The present invention provides lipid-based formulations for delivering, e.g., introducing, nucleic acid-lipid particles comprising an interference RNA molecule to a cell, and assays for optimizing the delivery efficiency of such lipid-based formulations.Type: GrantFiled: June 7, 2005Date of Patent: September 21, 2010Assignee: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Lorne R. Palmer, James Heyes
-
Patent number: 7745651Abstract: The present invention provides compositions comprising cationic lipids, liposomes and nucleic acid-lipid particles comprising the cationic lipids, and methods of using such compositions, liposomes, and nucleic acid-lipid particles.Type: GrantFiled: June 7, 2005Date of Patent: June 29, 2010Assignee: Protiva Biotherapeutics, Inc.Inventors: James Heyes, Ian MacLachlan, Lorne R. Palmer
-
Patent number: 7705195Abstract: The present invention is directed to methods using transgenic mice to screen for biologically active agents.Type: GrantFiled: June 4, 2003Date of Patent: April 27, 2010Assignee: Genentech, Inc.Inventors: Dorothy French, Avi J. Ashkenazi, Jean-Philippe F. Stephan, Luc Desnoyers
-
Patent number: 7663017Abstract: The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted H2 class I gene, a disrupted H2 class II gene, a functional HLA class I transgene, and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both H2 class I and class II molecules, wherein the transgenic mouse comprises a functional HLA class I transgene and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cell has the genotype HLA-A2+HLA-DR1+?2m°IA?°. The invention also relates to methods of using a transgenic mouse of the invention.Type: GrantFiled: July 2, 2004Date of Patent: February 16, 2010Assignee: Institut PasteurInventors: Yu-Chun Lone, Anthony Pajot, Claude Auriault, Veronique Pancre, François Lemonnier
-
Patent number: 7659058Abstract: The present invention relates to a method for the detection of epitope-specific T-cells and target epitopes of reactive T-cells. Furthermore, the present invention relates to vectors comprising a first promoter which is specifically inducible by the epitope-specific contact with a T-cell in antigen-presenting cells, a nucleic acid which is functionally linked to this first promoter and which encodes a marker gene, a second promoter which is constitutive in antigen-presenting cells, and a nucleic acid which is functionally linked to said second promoter. Furthermore, the present invention relates to antigen-presenting cells which are transduced with the vectors according to the invention.Type: GrantFiled: November 20, 2002Date of Patent: February 9, 2010Assignee: Lophius Biosciences GmbHInventor: Ludwig Deml
-
Patent number: 7638276Abstract: The invention describes a method for isolating one or more genetic elements encoding a gene product having a desired activity, comprising of the steps of: (a) compartmentalising genetic elements into microcapsules; (b) expressing the genetic elements to produce their respective gene products within the microcapsules; (c) sorting the genetic elements which produce the gene product having a desired activity. The invention enables the in vitro evolution of nucleic acids by repeated mutagenesis and iterative applications of the method of the invention.Type: GrantFiled: June 4, 2004Date of Patent: December 29, 2009Assignee: 454 Life Sciences CorporationInventors: Andrew Griffiths, Dan Tawfik
-
Patent number: 7582613Abstract: The invention provides adjuvants, immunogenic compositions, and methods useful for polynucleotide-based vaccination and immune response. In particular, the invention provides an adjuvant of cytofectin:co-lipid mixture wherein cytofectin is GAP-DMORIE.Type: GrantFiled: March 19, 2003Date of Patent: September 1, 2009Assignee: Vical IncorporatedInventor: Carl J Wheeler
-
Patent number: 7547546Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbours osteogenic progenitor cells and MHC?/? progenitor cells, and is useful to grow and repair human tissues including bone.Type: GrantFiled: October 8, 2004Date of Patent: June 16, 2009Assignee: Tissue Regeneration Therapeutics Inc.Inventors: John E. Davies, Dolores Baksh, Rahul Sarugaser, Morris Hosseini, Antony D. S. Lickorish
-
Patent number: 7527971Abstract: The present invention is directed to a new cell line, VIT4-G9, which has been deposited as ATCC Accession number PTA-8683.Type: GrantFiled: October 20, 2005Date of Patent: May 5, 2009Assignee: Vitro Diagnostics, Inc.Inventor: James R. Musick
-
Patent number: 7402730Abstract: Genetically engineered cells and animals are described that incorporate a mutated GHP1 allele. Animals that are homozygous for the mutated GHP1 allele are useful for the production of monoclonal antibodies against GHP1.Type: GrantFiled: February 3, 2006Date of Patent: July 22, 2008Assignee: Lexicon Pharmaceuticals, Inc.Inventors: Mary Jean Sparks, Wenhu Huang